vs
PEOPLES BANCORP INC（PEBO）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是PEOPLES BANCORP INC的1.7倍（$207.3M vs $118.7M），PEOPLES BANCORP INC净利率更高（24.4% vs -62.0%，领先86.5%），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 3.7%）
该公司是总部位于美国明尼苏达州明尼阿波利斯、在特拉华州注册的美国跨国银行机构。截至2025年，它是美国第五大银行，同时也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构。它主营银行、投资、抵押贷款等相关金融业务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
PEBO vs RARE — 直观对比
营收规模更大
RARE
是对方的1.7倍
$118.7M
净利率更高
PEBO
高出86.5%
-62.0%
两年增速更快
RARE
近两年复合增速
3.7%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $118.7M | $207.3M |
| 净利润 | $29.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | — | -54.7% |
| 净利率 | 24.4% | -62.0% |
| 营收同比 | — | 25.9% |
| 净利润同比 | -8.7% | 3.5% |
| 每股收益（稀释后） | $0.81 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PEBORARE
| Q1 26 | $118.7M | — | ||
| Q4 25 | $117.3M | $207.3M | ||
| Q3 25 | $115.2M | $159.9M | ||
| Q2 25 | $114.5M | $166.5M | ||
| Q1 25 | $112.4M | $139.3M | ||
| Q4 24 | $111.6M | $164.6M | ||
| Q3 24 | $113.7M | $139.5M | ||
| Q2 24 | $110.3M | $147.0M |
净利润PEBORARE
| Q1 26 | $29.0M | — | ||
| Q4 25 | $31.8M | $-128.6M | ||
| Q3 25 | $29.5M | $-180.4M | ||
| Q2 25 | $21.2M | $-115.0M | ||
| Q1 25 | $24.3M | $-151.1M | ||
| Q4 24 | $26.9M | $-133.2M | ||
| Q3 24 | $31.7M | $-133.5M | ||
| Q2 24 | $29.0M | $-131.6M |
营业利润率PEBORARE
| Q1 26 | — | — | ||
| Q4 25 | 32.4% | -54.7% | ||
| Q3 25 | 33.0% | -106.9% | ||
| Q2 25 | 24.0% | -64.8% | ||
| Q1 25 | 27.9% | -102.6% | ||
| Q4 24 | 31.2% | -74.3% | ||
| Q3 24 | 36.0% | -94.6% | ||
| Q2 24 | 32.5% | -79.1% |
净利率PEBORARE
| Q1 26 | 24.4% | — | ||
| Q4 25 | 27.1% | -62.0% | ||
| Q3 25 | 25.6% | -112.8% | ||
| Q2 25 | 18.5% | -69.0% | ||
| Q1 25 | 21.7% | -108.5% | ||
| Q4 24 | 24.1% | -80.9% | ||
| Q3 24 | 27.9% | -95.7% | ||
| Q2 24 | 26.3% | -89.5% |
每股收益（稀释后）PEBORARE
| Q1 26 | $0.81 | — | ||
| Q4 25 | $0.89 | $-1.28 | ||
| Q3 25 | $0.83 | $-1.81 | ||
| Q2 25 | $0.59 | $-1.17 | ||
| Q1 25 | $0.68 | $-1.57 | ||
| Q4 24 | $0.76 | $-1.34 | ||
| Q3 24 | $0.89 | $-1.40 | ||
| Q2 24 | $0.82 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.9M | $421.0M |
| 总债务越低越好 | $691.3M | — |
| 股东权益账面价值 | $1.2B | $-80.0M |
| 总资产 | $9.6B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.57× | — |
8季度趋势，按日历期对齐
现金及短期投资PEBORARE
| Q1 26 | $82.9M | — | ||
| Q4 25 | $189.0M | $421.0M | ||
| Q3 25 | $190.2M | $202.5M | ||
| Q2 25 | $186.1M | $176.3M | ||
| Q1 25 | $187.0M | $127.1M | ||
| Q4 24 | $217.7M | $174.0M | ||
| Q3 24 | $283.7M | $150.6M | ||
| Q2 24 | $235.9M | $480.7M |
总债务PEBORARE
| Q1 26 | $691.3M | — | ||
| Q4 25 | $204.1M | — | ||
| Q3 25 | $227.3M | — | ||
| Q2 25 | $232.4M | — | ||
| Q1 25 | $237.0M | — | ||
| Q4 24 | $238.1M | — | ||
| Q3 24 | $236.8M | — | ||
| Q2 24 | $234.3M | — |
股东权益PEBORARE
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $-80.0M | ||
| Q3 25 | $1.2B | $9.2M | ||
| Q2 25 | $1.2B | $151.3M | ||
| Q1 25 | $1.1B | $144.2M | ||
| Q4 24 | $1.1B | $255.0M | ||
| Q3 24 | $1.1B | $346.8M | ||
| Q2 24 | $1.1B | $432.4M |
总资产PEBORARE
| Q1 26 | $9.6B | — | ||
| Q4 25 | $9.6B | $1.5B | ||
| Q3 25 | $9.6B | $1.2B | ||
| Q2 25 | $9.5B | $1.3B | ||
| Q1 25 | $9.2B | $1.3B | ||
| Q4 24 | $9.3B | $1.5B | ||
| Q3 24 | $9.1B | $1.5B | ||
| Q2 24 | $9.2B | $1.6B |
负债/权益比PEBORARE
| Q1 26 | 0.57× | — | ||
| Q4 25 | 0.17× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.21× | — | ||
| Q2 24 | 0.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-100.8M |
| 自由现金流率自由现金流/营收 | — | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-472.0M |
8季度趋势，按日历期对齐
经营现金流PEBORARE
| Q1 26 | — | — | ||
| Q4 25 | $134.7M | $-99.8M | ||
| Q3 25 | $14.4M | $-91.4M | ||
| Q2 25 | $50.7M | $-108.3M | ||
| Q1 25 | $34.3M | $-166.5M | ||
| Q4 24 | $143.2M | $-79.3M | ||
| Q3 24 | $34.1M | $-67.0M | ||
| Q2 24 | $32.1M | $-77.0M |
自由现金流PEBORARE
| Q1 26 | — | — | ||
| Q4 25 | $128.7M | $-100.8M | ||
| Q3 25 | $12.7M | $-92.7M | ||
| Q2 25 | $49.2M | $-110.7M | ||
| Q1 25 | $31.5M | $-167.8M | ||
| Q4 24 | $136.4M | $-79.5M | ||
| Q3 24 | $33.2M | $-68.6M | ||
| Q2 24 | $30.2M | $-79.0M |
自由现金流率PEBORARE
| Q1 26 | — | — | ||
| Q4 25 | 109.7% | -48.6% | ||
| Q3 25 | 11.0% | -58.0% | ||
| Q2 25 | 43.0% | -66.5% | ||
| Q1 25 | 28.1% | -120.5% | ||
| Q4 24 | 122.2% | -48.3% | ||
| Q3 24 | 29.2% | -49.2% | ||
| Q2 24 | 27.4% | -53.7% |
资本支出强度PEBORARE
| Q1 26 | — | — | ||
| Q4 25 | 5.1% | 0.5% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 2.4% | 1.0% | ||
| Q4 24 | 6.1% | 0.1% | ||
| Q3 24 | 0.8% | 1.2% | ||
| Q2 24 | 1.7% | 1.4% |
现金转化率PEBORARE
| Q1 26 | — | — | ||
| Q4 25 | 4.24× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 2.39× | — | ||
| Q1 25 | 1.41× | — | ||
| Q4 24 | 5.32× | — | ||
| Q3 24 | 1.08× | — | ||
| Q2 24 | 1.11× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PEBO
| Net Interest Income | $90.4M | 76% |
| Noninterest Income | $28.3M | 24% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
